Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Amycretin, an oral weight loss pill developed by the makers of Wegovy, led to a 13.1% weight loss over three months in early ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

A daily diet pill has shown promising results in early trials, with participants losing an average of 13% of their body ...

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Amycretin mimics the actions of glucagon-like peptide-1 (GLP-1) and amylin, hormones that play a role in reducing blood sugar ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Novo Nordisk’s Amycretin Outperforms Wegovy in Phase I Study Novo Nordisk’s full data from the phase I study demonstrated that amycretin led to faster weight loss than Wegovy. The data showed ...